xmlui.dri2xhtml.structural.head-subtitle

Monitoring of efficacy and safety of artemisininbased anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzania

Show simple item record

dc.contributor.author Shayo, Alex
dc.contributor.author Buza, Joram
dc.contributor.author Ishengoma, Deus S
dc.date.accessioned 2019-10-10T06:21:55Z
dc.date.available 2019-10-10T06:21:55Z
dc.date.issued 2015
dc.identifier.uri DOI 10.1186/s12936-015-0649-8
dc.identifier.uri http://dspace.nm-aist.ac.tz/handle/123456789/475
dc.description Research Article published by BioMed Central en_US
dc.description.abstract Background: Prompt diagnosis and effective treatment are considered the cornerstones of malaria control and artemisinin-based combination therapy (ACT) is currently the main anti-malarial drugs used for case management. After deployment of ACT due to widespread parasite resistance to the cheap and widely used anti-malarial drugs, chloroquine and sulphadoxine/pyrimethamine, the World Health Organization recommends regular surveillance to monitor the efficacy of the new drugs. The present paper assessed the implementation of anti-malarial efficacy testing for monitoring the therapeutic efficacy of ACT for treatment of uncomplicated malaria in Tanzania before and after policy changes in 2006. Methods: A literature search was performed for published clinical trials conducted in Tanzania from 2001 to 2014. It focused on studies which assessed at least one form of ACT for treatment of uncomplicated falciparum malaria in children less than 10 years and reported efficacy and safety of the tested anti-malarials. References were imported into the Endnote library and duplicates removed. An electronic matrix was developed in Microsoft Excel followed by full text review with predetermined criteria. Studies were independently assessed and information related to ACT efficacy and safety extracted. Results: Nine papers were selected from 125 papers screened. The efficacy of both artemether-lumefantrine (AL) and artesunate-amodiaquine (AS + AQ) against uncomplicated P. falciparum infections in Tanzania was high with PCRcorrected cure rates on day 28 of 91-100% and 88-93.8%, respectively. The highest day-3 parasite positivity rate was 1.4%. Adverse events ranged from mild to serious but were not directly attributed to the drugs. Conclusion: ACT is efficacious and safe for treatment of uncomplicated malaria in Tanzania. However, few trials were conducted in Tanzania before and after policy changes in 2006 and thus more surveillance should be urgently undertaken to detect future changes in parasite sensitivity to ACT. en_US
dc.language.iso en en_US
dc.publisher BioMed Central en_US
dc.subject Combination therapy en_US
dc.subject Plasmodium falciparum and Tanzania en_US
dc.title Monitoring of efficacy and safety of artemisininbased anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzania en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search Our NM-AIST IR


Browse NM-AIST IR

My NM-AIST IR Account

Statistics